Eyeworld

MAY 2017

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: http://digital.eyeworld.org/i/815472

Contents of this Issue

Navigation

Page 94 of 94

IMPORTANT SAFETY INFORMATION OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% must be added to irrigation solution prior to intraocular use. OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma. The most commonly reported adverse reactions at 2-24% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation. Use of OMIDRIA in children has not been established. INDICATIONS AND USAGE OMIDRIA is added to ophthalmic irrigation solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain. Reference: 1. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2016. Please see the Full Prescribing Information at www.omidria.com/prescribinginformation. * Individual insurance coverage and policies may vary, and Omeros does not guarantee insurance coverage or payment. Omeros offers payments under the OMIDRIAssure "We Pay the Difference" program on behalf of qualifying patients. OMIDRIAssure is subject to change without notice. Visit www.omidria.com OMEROS®, the OMEROS logo®, OMIDRIA®, the OMIDRIA logo®, and OMIDRIAssure® are registered trademarks of Omeros Corporation. © Omeros Corporation 2017, all rights reserved. 2017-022 • Preempt miosis and inhibit postoperative pain 1 • Block the surgically induced inflammatory cascade with the first and only NSAID FDA-approved for intracameral use 1 • Eliminate the risks and liabilities of compounded products by using FDA-approved, GMP-manufactured OMIDRIA • Avoid reimbursement difficulties by using broadly covered OMIDRIA and the OMIDRIAssure ® services (OMIDRIAssure.com)* CHOOSE OMIDRIA FOR YOUR NEXT CATARACT SURGERY PATIENT THE POWER OF PREEMPTION OMIDRIA ® is the first and only FDA-approved drug that provides continuous intracameral delivery of NSAID and mydriatic/anti-miotic therapy during cataract surgery 1

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld - MAY 2017